BridgeBio has substantially advanced its development of an new therapy for ATTR-CM, employing Attruby. Early patient data reveals significant outcomes for individuals diagnosed with a serious illness. The effort https://biotech318937.blog-a-story.com/24014352/bridgebio-progresses-attr-cm-therapy-through-attruby